Tyrosine kinase inhibitor STI-571/gleevec down-regulates the β-catenin signaling activityLAN ZHOU; AN, Naili; JAE YOON PARKA et al.Cancer letters. 2003, Vol 193, Num 2, pp 161-170, issn 0304-3835, 10 p.Article

Metabolism and disposition of imatinib mesylate in healthy volunteersGSCHWIND, Hans-Peter; PFAAR, Ulrike; BIN PENG et al.Drug metabolism and disposition. 2005, Vol 33, Num 10, pp 1503-1512, issn 0090-9556, 10 p.Article

Treatment of gastrointestinal stromal tumors with imatinib mesylate : A major breakthrough in the understanding of tumor-specific molecular characteristicsDE MESTIER, Philippe; DES GUETZ, Gaetan; BLANKE, Charles et al.World journal of surgery. 2005, Vol 29, Num 3, pp 357-362, issn 0364-2313, 6 p.Article

Gene expression signatures associated with the resistance to imatinibCHUNG, Y.-J; KIM, T.-M; KANG, H.-M et al.Leukemia. 2006, Vol 20, Num 9, pp 1542-1550, issn 0887-6924, 9 p.Article

Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: A case reportTAN, D; HWANG, W; NG, H. J et al.International journal of hematology. 2004, Vol 80, Num 1, pp 75-77, issn 0925-5710, 3 p.Article

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeKLION, Amy D; ROBYN, Jamie; AKIN, Cem et al.Blood. 2004, Vol 103, Num 2, pp 473-478, issn 0006-4971, 6 p.Article

Case 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylateCHACON, Matias; ROCA, Enrique; HUERTAS, Eduardo et al.Journal of clinical oncology. 2005, Vol 23, Num 7, pp 1580-1582, issn 0732-183X, 3 p.Article

A report of three patients treated with Immunocell therapy with imatinib mesylateKANEKO, Toru; GOTO, Shigenori; KUSHIMA, Yoshiaki et al.Anticancer research. 2004, Vol 24, Num 5C, pp 3303-3309, issn 0250-7005, 7 p.Conference Paper

Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia? Authors' replyCHUNDURI, S; DOBOGAI, L. C; BRUNO, A et al.Leukemia. 2005, Vol 19, Num 3, pp 456-457, issn 0887-6924, 2 p.Article

Molecular responses in patients with chronic myelogenous leukemia in chronic phasetreated with imatinib mesylateCORTES, Jorge; TALPAZ, Moshe; RIOS, Mary B et al.Clinical cancer research. 2005, Vol 11, Num 9, pp 3425-3432, issn 1078-0432, 8 p.Article

Another look at imatinib mesylateSTREBHARDT, Klaus; ULLRICH, Axel.The New England journal of medicine. 2006, Vol 355, Num 23, pp 2481-2482, issn 0028-4793, 2 p.Article

Enfin un traitement efficace dans les sarcomes digestifs indifférenciés (tumeurs stromales) = At last, an effective therapy for non-differentiated GI sarcomas (gastrointestinal stromal tumor)DES GUETZ, G; DE MESTIER, Ph.Journal de chirurgie (Paris. 1908). 2002, Vol 139, Num 5, pp 268-273, issn 0021-7697Article

First case of immune-mediated haemolytic anaemia associated to imatinib mesylateZAGO NOVARETTI, Marcia C; FONSECA, Guilherme H. H; CONCHON, Monika et al.European journal of haematology. 2003, Vol 71, Num 6, pp 455-458, issn 0902-4441, 4 p.Article

PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activationHIRAI, T; MASAKI, T; KURATSUNE, M et al.Clinical and experimental immunology (Print). 2006, Vol 144, Num 2, pp 353-361, issn 0009-9104, 9 p.Article

Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcomaKATAYAMA, Rieko; HUELSMEYER, Michael K; MARR, Amanda K et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 1, pp 25-33, issn 0344-5704, 9 p.Article

Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571LIU, Wei-Hua; MAKRIGIORGOS, G. Mike.Leukemia research. 2003, Vol 27, Num 11, pp 979-982, issn 0145-2126, 4 p.Article

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or ST1571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell linesAVRAMIS, Ioannis A; LAUG, Walter E; SAUSVILLE, Edward A et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 4, pp 307-318, issn 0344-5704, 12 p.Article

Dysregulation of bone remodeling by imatinib mesylateVANDYKE, Kate; FITTER, Stephen; DEWAR, Andrea L et al.Blood. 2010, Vol 115, Num 4, pp 766-774, issn 0006-4971, 9 p.Article

Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemiasMARANGON, Elena; CITTERIO, Marco; SALA, Federica et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 3, pp 563-566, issn 0344-5704, 4 p.Article

Ocular Side Effects Associated with Imatinib Mesylate and Perifosine for Gastrointestinal StromalTumorSERDAR DOGAN, S; ESMAELI, Bita.Hematology/oncology clinics of North America. 2009, Vol 23, Num 1, issn 0889-8588, ix, 109-114 [7 p.]Article

Major Response to Imatinib Mesylate in KIT-Mutated MelanomaHODI, F. Stephen; FRIEDLANDER, Philip; FISHER, David E et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 2046-2051, issn 0732-183X, 6 p.Article

Altered bone and mineral metabolism in patients receiving imatinib mesylateBERMAN, Ellin; NICOLAIDES, Maria; MAKI, Robert G et al.The New England journal of medicine. 2006, Vol 354, Num 19, pp 2006-2013, issn 0028-4793, 8 p.Article

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaQUINTAS-CARDAMA, Alfonso; KANTARJIAN, Hagop; XIAN ZHOU et al.Blood. 2005, Vol 105, Num 6, pp 2281-2286, issn 0006-4971, 6 p.Article

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivationMATEI, Daniela; CHANG, David D; JENG, Meei-Huey et al.Clinical cancer research. 2004, Vol 10, Num 2, pp 681-690, issn 1078-0432, 10 p.Article

Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylateREICHARDT, P; SCHNEIDER, U; STROSZCZYNSKI, C et al.Journal of clinical pathology. 2004, Vol 57, Num 2, pp 215-217, issn 0021-9746, 3 p.Article